During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, discussed his approach to recognizing and managing adverse events related to treatment with cabozantinib and nivolumab in patients with advanced renal cell carcinoma. This is the second article based on this event.
Targeted Oncology: What toxicities are the most serious with the combination of nivolumab (Opdivo) plus cabozantinib (Cabometyx) compared with sunitinib (Sutent) based on the CheckMate 9ER trial (NCT03141177) in metastatic renal cell carcinoma (mRCC)?
AGARWAL: If you if you look at grade 3 or 4 toxicities, which is easy to compare, they are not very different [since] cabozantinib and sunitinib are both VEGF tyrosine kinase inhibitors [TKIs]. Diarrhea, hand-foot syndrome, and hypertension are the most common ones, and they’re very similar in both arms.1 But I don’t think nivolumab was contributing much beyond isolated elevation of liver enzymes. These are quite common, mostly grade 1 or 2. I don’t change anything unless they keep rising. Or I hold off on nivolumab for some time, and then I restart and most patients do well. I see lipase elevation quite often, but it’s mostly asymptomatic lipase elevation without pancreatitis. But other than that, I don’t see much difference between the arms as far as grade 3 or 4 adverse events are concerned.
Do you commonly check lipase levels in your patients?
During the clinical trials we have to check lipase. In my regular clinic, I don’t check lipase. But we have to check lipase in trials, and they go up and you don’t know what to do with it because the patient is doing fine. They were getting scans, and there was no evidence of pancreatitis on the scan, and they were completely asymptomatic. So we don’t know what to do with it. If they are having pain, that’s a different story.
If aspartate aminotransferase [AST] or alanine aminotransferase [ALT] are increasing, how do you know if it is necessary to hold nivolumab or cabozantinib?
I stop cabozantinib first. Ninety percent of these patients have grade 1 or 2 AST/ALT elevation because of TKIs.... If you stop cabozantinib, AST goes down within 4 or 5 days. That’s the first test I do, whether it is because of the TKI, which is the most common cause of AST elevation.
But then I also keep in mind that there are 3% or 4% patients who will be developing immune-related hepatitis. I don’t want to miss that. I stop cabozantinib first, then nivolumab is automatically held when these patients come to the clinic. If they get better with holding off on cabozantinib, then I continue with nivolumab.
Very rarely we see AST/ALT keeps going up despite stopping cabozantinib. Because if it is because of nivolumab, holding off on 1 dose is not going to make a change in immune hepatitis. Even though nivolumab was given 4 weeks before, it will continue to work to cause immune hepatitis. So if they have a second elevation, I start them on prednisone. I don’t wait for grade 3 or grade 4. I stop cabozantinib and I recheck the liver enzymes and if they have continued elevation of liver enzymes, I start them on prednisone at 1 mg/kg, not 2 mg/kg. One milligram per kilogram often does the trick with isolated enzyme elevation. And I only do that if [it continues] despite cabozantinib discontinuation and 7 days after.
This is probably one of the most challenging situations we used to face during the clinical trials. If someone has diarrhea—cabozantinib, axitinib [Inlyta], and all of them cause diarrhea, and there were no guidelines at the time and we used to think, what should we do now? Then we realized axitinib, cabozantinib, lenvatinib [Lenvima] may have different half-lives, but when we hold them, diarrhea gets better in 2 days. That’s how I start contemplating starting steroids.
Reference:
1. Powles T, Choueiri TK, Burotto M, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol. 2022;40(suppl_6):350. doi:10.1200/JCO.2022.40.6_suppl.350
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More